Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
515.20
-10.10(-2.00%)
At close: 4:00 PM EDT
515.20
-10.10(-2.00%)
Day’s Range― - ―
52-Week Range309.00 - 3,000.00
Previous CloseN/A
Volume9.36K
Average Volume (3M)23.73K
Market Cap
₪19.41M
Enterprise Value-5.67M
Total Cash (Recent Filing)₪7.04M
Total Debt (Recent Filing)₪49.00K
Price to Earnings (P/E)―
Beta-0.54
Next Earnings
Apr 01, 2027EPS Estimate
-122.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.54
Shares Outstanding6,063,093
10 Day Avg. Volume9,466
30 Day Avg. Volume23,726
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt limits interest burden and reduces near-term balance-sheet pressure. This gives Can-Fite more flexibility to direct available capital toward clinical development rather than debt service, although it does not eliminate the company’s broader funding needs.
High Gross MarginGross profit that broadly matches revenue suggests reported costs are not consuming the sales base at the gross-profit level. If the company can expand candidate-related revenue, this structure could allow additional sales to contribute meaningfully before operating expenses.
Focused Drug-development PlatformA defined A3AR platform gives Can-Fite a coherent scientific focus rather than an unrelated collection of programs. Its candidates have been investigated across psoriasis, arthritis, liver disease, and cancer, creating several potential clinical development paths.
Bears Say
Minimal And Declining RevenueThe very small revenue base and multi-year decline show that Can-Fite has not yet established meaningful commercial scale. This leaves the business dependent on successful development, partnering, or financing rather than internally generated operating revenue.
Persistent Losses And Cash BurnLarge recurring losses are translating into substantial cash outflows, so operations are consuming rather than generating funding. Continued burn can constrain clinical investment and increase reliance on external capital while candidates remain in development.
Shrinking Equity And Financing RiskThe substantial reduction in equity reflects the cumulative impact of ongoing losses and weak returns on shareholder capital. With debt low but cash burn high, the company may need additional financing, creating potential dilution and less financial flexibility.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 309.00 and its highest was 3000.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪19.41M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 173 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Sep 08, 2026. The company reported -189.918 earnings per share for the quarter, missing the consensus estimate of -50.543 by -139.376.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -122.53.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 6,063,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -189.918 in its last earnings report, missing expectations of -50.543. Following the earnings report the stock price went down -5.668%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.